William Blair Has Bullish Estimate for CVRx FY2024 Earnings

CVRx, Inc. (NASDAQ:CVRX) – Research analysts at William Blair lifted their FY2024 earnings estimates for shares of CVRx in a research report issued to clients and investors on Tuesday, January 14th. William Blair analyst M. Andrew now expects that the company will earn ($2.62) per share for the year, up from their previous forecast of ($2.65). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.62) per share. William Blair also issued estimates for CVRx’s Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.82) EPS.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. The business had revenue of $13.37 million for the quarter, compared to analyst estimates of $13.28 million. During the same quarter last year, the company earned ($0.43) EPS.

CVRX has been the topic of a number of other reports. Craig Hallum raised their target price on shares of CVRx from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $14.00 target price on shares of CVRx in a research note on Wednesday, October 23rd. Canaccord Genuity Group raised their target price on shares of CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Lake Street Capital raised their target price on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.67.

CVRx Stock Performance

NASDAQ:CVRX opened at $17.30 on Thursday. CVRx has a 1 year low of $6.40 and a 1 year high of $29.23. The firm’s fifty day simple moving average is $14.04 and its 200 day simple moving average is $11.05. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $419.70 million, a PE ratio of -6.41 and a beta of 1.26.

Institutional Trading of CVRx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in CVRx in the 3rd quarter worth $108,000. XTX Topco Ltd acquired a new stake in CVRx in the 3rd quarter worth $150,000. Rhumbline Advisers lifted its holdings in shares of CVRx by 28.8% during the 2nd quarter. Rhumbline Advisers now owns 17,260 shares of the company’s stock worth $207,000 after acquiring an additional 3,863 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of CVRx during the 2nd quarter worth about $218,000. Finally, Jane Street Group LLC lifted its holdings in shares of CVRx by 36.1% during the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after acquiring an additional 5,053 shares during the period. 75.27% of the stock is currently owned by institutional investors and hedge funds.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.